Cantor Fitzgerald Reiterates Overweight on Bristol-Myers Squibb, Maintains $75 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has reiterated an Overweight rating on Bristol-Myers Squibb (NYSE:BMY) and maintained a $75 price target.
September 15, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Bristol-Myers Squibb and maintained a $75 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Bristol-Myers Squibb. The maintained price target of $75 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100